Tumor NLRP3 inflammasome activity mediates resistance to Anti-PD-1 immunotherapy in advanced gastroesophageal cancer

被引：0
|
作者：
Yarla, Nagendra
Howell, Kaylee
Y-Van Nguyen
Niedwiecki, Donna
Uronis, Hope
Strickler, John
DeVito, Nicholas C.
Theivanthiran, Bala
Hanks, Brent A.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-7521
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7521
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy
    Theivanthiran, Balamayoora
    Evans, Kathy S.
    DeVito, Nicholas C.
    Plebanek, Michael
    Sturdivant, Michael
    Wachsmuth, Luke P.
    Salama, April K. S.
    Kang, Yubin
    Hsu, David
    Balko, Justin M.
    Johnson, Douglas B.
    Starr, Mark
    Nixon, Andrew B.
    Holtzhausen, Alisha
    Hanks, Brent A.
    JOURNAL OF CLINICAL INVESTIGATION, 2020, 130 (05): : 2570 - 2586
  • [2] A tumor PD-L1-NLRP3 inflammasome signaling axis drives adaptive resistance to anti-PD-1 immunotherapy
    Theivanthiran, Balamayooran
    Evans, Kathy
    DeVito, Nicholas
    Plebanek, Michael
    Sturdivant, Michael
    Holtzhausen, Alisha
    Wachsmuth, Luke
    Salama, April
    Kang, Yubin
    Hsu, David
    Balko, Justin
    Johnson, Douglas
    Starr, Mark
    Nixon, Andrew
    Hanks, Brent
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [3] RACK1 Mediates NLRP3 Inflammasome Activation by Promoting NLRP3 Active Conformation and Inflammasome Assembly
    Duan, Yanhui
    Zhang, Lingzhi
    Angosto-Bazarra, Diego
    Pelegrin, Pablo
    Nunez, Gabriel
    He, Yuan
    CELL REPORTS, 2020, 33 (07):
  • [4] Potential of inhibition of NLRP3 inflammasome in enhancement of immunotherapy in prostate cancer
    Kalkusova, Katerina
    Stakheev, Dmitry
    Taborska, Pavla
    Bartunkova, Jirina
    Smrz, Daniel
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 : 785 - 785
  • [5] HSP90 Mediates IFNγ-Induced Adaptive Resistance to Anti-PD-1 Immunotherapy
    Liu, Ke
    Huang, Jun
    Liu, Jiao
    Li, Changfeng
    Kroemer, Guido
    Tang, Daolin
    Kang, Rui
    CANCER RESEARCH, 2022, 82 (10) : 2003 - 2018
  • [6] Anti-PD-1 monoclonal antibody Cancer immunotherapy
    da Silva, R. Moreira
    DRUGS OF THE FUTURE, 2014, 39 (01) : 15 - 24
  • [7] Breaking the barriers: Overcoming cancer resistance by targeting the NLRP3 inflammasome
    Far, Nazanin Pazhouhesh
    Varnousafaderani, Mahsa Hajiheidari
    Faghihkhorasani, Ferdos
    Etemad, Sareh
    Abdulwahid, Al-Hasnawi Rasool Riyadh
    Bakhtiarinia, Negar
    Mousaei, Afsaneh
    Dortaj, Elahe
    Karimi, Soroush
    Ebrahimi, Nasim
    Aref, Amir Reza
    BRITISH JOURNAL OF PHARMACOLOGY, 2025, 182 (01) : 3 - 25
  • [8] Nanovaccine that activates the NLRP3 inflammasome enhances tumor specific activation of anti-cancer immunity
    Manna, Saikat
    Maiti, Sampa
    Shen, Jingjing
    Weiss, Adam
    Mulder, Elizabeth
    Du, Wenjun
    Esser-Kahn, Aaron P.
    BIOMATERIALS, 2023, 296
  • [9] Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy
    Sahni, Sakshi
    Valecha, Gautam
    Sahni, Ankit
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2018, 10 (12)
  • [10] Innovative cancer immunotherapy, anti-PD-1 antibody Nivolumab
    Shibayama, Shiro
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2017, 133 (03) : S40 - S40
12345